

## **Autolomous expands digital orchestration solutions from CGT to wider biopharma sectors**

**Increased complexity across regulation, therapeutic development, supply chains, technology and AI adoption and manufacturing driving demand across biopharma sector for Autolomous digitalization solutions**

**London, UK, May 6, 2026** – [Autolomous](#), a developer of critical manufacturing management systems for advanced therapies, today broadening the availability of its suite of digitalized systems from the cell and gene therapy sector to across the wider biopharma and life science sectors.

Autolomous has demonstrated the requirement for, and benefits of, digitalization in the CGT sector, over a seven-year program. Autolomous has faced increasing demand from developers and companies involved outside CGT as supply chains in the wider biopharma sector have continued to increase in complexity.

These complexities involve an increased use of biologics and targeted therapies, increasingly complex therapeutic development pathways, distributed and internationalized manufacturing programs, increased technology and data volumes, fragmented systems, real-time coordination amongst stakeholders, as well as complex supply chains, wider patient numbers and combination therapies. These multiple factors have also highlighted the need for orchestration, traceability and data harmonization across wider biopharma development.

A major additional area of demand is the increased use of data generated by the rising adoption of AI and advanced analytics. This in turn creates data management, and differentiated data access challenges. Advances in technology within wider biopharma have created the similar levels of challenges in managing data handling, scale, and coordination that CGT previously experienced with the requirement for the manufacture, supply and delivery of personalized therapies.

As a result, Autolomous have broadened its suite of digitalized critical manufacturing management systems originally designed and validated for CGTs, and made them available across the wider biopharma sector. The serving of the CGT sector will continue to remain a core focus. However, expansion across the biopharma sector has commenced, and will intensify over the next 12 to 24 months. This will involve initial deployments for partnerships already in progress and the gradual phased scaling into additional therapeutic areas and operational domains.

The first areas outside CGT defined by the highest demand will involve the first phase of expansion. This includes biologics testing, and the RNA fields, involving mRNA. There are also sectors which have immediate existing infrastructure gaps, including blood center operations. Finally, in the first phase, the radiotherapeutics sector has a clear demand for orchestration and data integration.



Autolomous will continue iteration and further development of its platform and technologies based on both CGT and wider biopharma requirements in tandem. This will create cross-pollination and shared values across both sectors. Autolomous has the capability to bridge gaps between previously siloed sectors that have been forced to integrate due to increasing numbers of combination therapies.

*“Drug development across the wider biopharma sector has continued to increase in complexity. The further tightening of regulatory requirements, and the data avalanche, created by increased technology use and AI, has created a perfect storm for all those involved in therapeutic development. Whilst vastly increasing amounts of data are a real challenge to the wider biopharma sectors, the CGT sector has had to deal with this challenge as it has evolved,” said Alexander Seyf, CEO, Autolomous. “Autolomous was founded specifically to deal with exactly these problems, and the company has evolved in step with the increases of complexity of the CGT sector. We are now working with a number of companies across the biopharma sector to provide solutions to their increasingly varied challenges. Following some internal key appointments, we have now decided to maintain a core focus on CGT, but also roll-out our digital orchestration solutions across the wider biopharma sector in a number of phases. Autolomous will continue to scale throughout this expansion process.”*

### **About Autolomous**

Autolomous helps life sciences customers achieve significant cost and time savings and build resilient manufacturing and supply chains through end-to-end digitization. Powered by advanced technology and artificial intelligence, autoloMATE® is a cloud-native, modular platform that integrates seamlessly with existing systems. By creating a digital backbone across manufacturing and supply chain operations - covering planning, execution, data management, quality control, reporting, and release - autoloMATE delivers measurable gains in productivity, scalability, and cost-effectiveness. Its modular architecture allows each deployment to be configured precisely to customer needs, while the intuitive design ensures ease of use across the organization. Autolomous serves pharma and biotech companies, CROs and CDMOs, blood centers, and non-profit organizations worldwide. Explore more at [www.autolomous.com](http://www.autolomous.com).

### **For more information contact:**

Neil Hunter

Hunter PR

[neil@hunterpr.biz](mailto:neil@hunterpr.biz)

+44 7821 255568